NorthLinks Bio develops HEX17, a self-administered intranasal spray engineered as a multivalent carbohydrate-binding module (mCBM) designed to mask host sialic acid cell receptors and prevent viral entry. The company emerged from a corporate reorganization of Pneumagen Ltd. and officially launched after raising $34M led by RA Capital Management. Human challenge studies completed by the company demonstrated an approximate 50% reduction in symptomatic influenza infection. NorthLinks plans to use the new funding to advance HEX17 toward Phase 2b readiness, expand its glycan-targeted platform, support manufacturing operations, and establish primary corporate infrastructure in the U.S. The company is led by CEO Fanny Cavalie9 and maintains research operations in St Andrews, Scotland, while being headquartered in Boston, Massachusetts.

Total raised

$34M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2026